OTCMKTS:LZAGY - Lonza Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$54.66
▲ +1.27 (2.38%)

This chart shows the closing price for LZAGY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lonza Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LZAGY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LZAGY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Lonza Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $54.66.

This chart shows the closing price for LZAGY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Lonza Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/20/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform
4/4/2022Morgan StanleyLower Price TargetEqual Weight ➝ Equal WeightCHF 800 ➝ CHF 785
2/10/2022Stifel NicolausUpgradeHold ➝ Buy
1/4/2022JPMorgan Chase & Co.Boost Price TargetCHF 850 ➝ CHF 900
10/20/2021UBS GroupUpgradeNeutral ➝ Buy
10/15/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
9/17/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight
9/8/2021JPMorgan Chase & Co.Reiterated RatingOverweight
7/29/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/29/2021Societe GeneraleReiterated RatingBuy
7/28/2021CitigroupReiterated RatingNeutral
7/28/2021Credit Suisse GroupReiterated RatingOutperform
7/2/2021Societe GeneraleReiterated RatingBuy
6/8/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
5/11/2021Morgan StanleyReiterated RatingOverweight
2/23/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
2/16/2021Deutsche Bank AktiengesellschaftReiterated RatingBuy
2/11/2021William BlairReiterated RatingOutperform
2/10/2021Berenberg BankReiterated RatingBuy
2/2/2021Morgan StanleyReiterated RatingOverweight
1/8/2021Morgan StanleyReiterated RatingOverweight
11/11/2020UBS GroupReiterated RatingNeutral
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
10/21/2020Societe GeneraleReiterated RatingBuy
10/2/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
9/14/2020Morgan StanleyReiterated RatingOverweight
9/4/2020Societe GeneraleReiterated RatingBuy
8/13/2020Credit Suisse GroupReiterated RatingOutperform
7/30/2020Morgan StanleyReiterated RatingOverweight
7/8/2020UBS GroupReiterated RatingNeutral
6/24/2020Morgan StanleyReiterated RatingOverweight
5/14/2020UBS GroupDowngradeBuy ➝ Neutral
1/31/2019Bank of AmericaDowngradeBuy ➝ Neutral
7/19/2017Jefferies Financial GroupUpgradeHold ➝ Buy
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Lonza Group logo
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $54.66
Low: $53.42
High: $54.66

50 Day Range

MA: $55.37
Low: $50.05
High: $60.24

52 Week Range

Now: $54.66
Low: $49.70
High: $86.31

Volume

347,700 shs

Average Volume

198,073 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

0.16%

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Lonza Group?

The following equities research analysts have issued reports on Lonza Group in the last twelve months: Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, Stifel Nicolaus, and UBS Group AG.
View the latest analyst ratings for LZAGY.

What is the current price target for Lonza Group?

0 Wall Street analysts have set twelve-month price targets for Lonza Group in the last year.
View the latest price targets for LZAGY.

What is the current consensus analyst rating for Lonza Group?

Lonza Group currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LZAGY will outperform the market and that investors should add to their positions of Lonza Group.
View the latest ratings for LZAGY.

What other companies compete with Lonza Group?

How do I contact Lonza Group's investor relations team?

Lonza Group's physical mailing address is Muenchensteinerstrasse 38, Basel V8, 4002. The company's listed phone number is (161) 316-8111 and its investor relations email address is [email protected] The official website for Lonza Group is www.lonza.com. Learn More about contacing Lonza Group investor relations.